ライフサイエンスコーパス: L-leucine

1 ), and helical, hydrophobic segments of poly(l-leucine).

2 isolates produced acetone in the presence of L-leucine.

3 approximately 0.61 mol of acetone per mol of L-leucine.

4 ain amino acids, L-isoleucine, L-valine, and L-leucine.

5 ited for uptake and distribution of N-acetyl-L-leucine.

6 the production of alpha-ketoisocaproate from L-leucine.

7 ject to slow-onset, allosteric inhibition by l-leucine.

8 or the improvement in anemia associated with L-leucine.

9 in response to treatment with the amino acid L-leucine.

10 nobicyclo[2.2.1]heptane-2-carboxylic acid or l-leucine.

11 itivity to the inhibitors L-homoarginine and L-leucine.

12 hain amino acids L-isoleucine, L-valine, and L-leucine.

13 ort was monitored by measuring the uptake of L-leucine.

14 )-pyridine], the DGL inhibitor THL [N-formyl-l-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]meth

15 e-1-yl) amino acid (amino acid=L-valine (1), L-leucine (2), L-isoleucine (3), L-tryptophan (4), L-phe

16 nine into the brain, mice were injected with L-leucine (300 mg/kg, IP) immediately before kynurenine

17 S, 0.83 mg/kg IP) or saline and treated with L-leucine (50 mg/kg, IP) or vehicle administered before

18 Rps14-deficient embryos with the amino acid L-leucine, a known activator of mRNA translation.

19 Treatment of cells with lactulosyl-l-leucine, a synthetic T antigen antagonist that targets

20 beta-alanine act as structure-breaker, while L-leucine acts as structure-maker both in water and in a

21 ddition to catabolite repression by glucose, l-leucine acts by inhibiting the binding of Lrp to the p

22 -norlaudanosine with 1 equiv of (-)-N-acetyl-l-leucine afforded the leucinate salt (+)-13 (99:1 dr).

23 xidation, N-oxalylglycine, L-pipecolic acid, L-leucine, alpha-ketoglutarate, glyoxylic acid, and L-or

24 l-Leucine aminopeptidases (LAPs) are implicated in the p

25 (alpha-ketoglutarate, ammonia, and NADH) and L-leucine (an activator of glutamate dehydrogenase) in t

26 oxylic acid (anti-(18)F-FACBC)is a synthetic l-leucine analog that has excellent in vitro uptake with

27 alkaline pH and exhibits increased rates of l-leucine and 3,3'-dihexyloxacarbocyanine iodide uptake,

28 iniPERM bioreactor in the presence of [U-14C]L-leucine and [U-14C]D-glucose.

29 The synthesis begins with l-leucine and affords gram quantities of the N(a) -Boc-N

30 n domains (A1-PCP1), specifically adenylates l-leucine and d-leucine in a 6:1 ratio, and it can be co

31 structure of two protected amino acids, FMOC-l-leucine and FMOC-l-valine, and a dipeptide, N-acetyl-l

32 The conserved effect of L-leucine and insulin/sugar suggests a key role for ener

33 it is derived from acetate, L-phenylalanine, L-leucine and L-cysteine.

34 present study we show that NMB0573 binds to l-leucine and l-methionine and have solved the structure

35 d transporter was examined through uptake of L-leucine and L-phenylalanine and provided Km and Vmax v

36 N-Palmitoyl-l-leucine and N-palmitoyl-l-methionine were found to hav

37 Finally, in mammals, L-leucine and sucrose administration induced digit regen

38 was increased by feeding with the amino acid L-leucine and the growth hormone insulin.

39 catalyze the hydroxylation of l-isoleucine, l-leucine, and l-alpha-amino-delta-carbamoylhydroxyvaler

40 Branched-chain amino acids L-isoleucine, L-leucine, and L-valine (ILV) activate CodY both in vivo

41 motactic responses to L-aspartate, L-serine, L-leucine, and Ni(2+) of WT and chemotactic-mutant strai

42 solution was benchmarked using L-isoleucine, L-leucine, and various other isobaric and isomeric metab

43 A series of L-leucine aniline analogues were synthesized that contai

44 Furthermore, the therapeutic response to L-leucine appeared specific for Rps19-deficient hematopo

45 l-tyrosine, l-tryptophan, l-methionine, and l-leucine, are converted to the corresponding alpha-hydr

46 hisms at FcgammaRIIIA-48: leucine/leucine (L/L), leucine/arginine (L/R), and leucine/histidine (L/H).

47 individual peaks, we identified N-palmitoyl-l-leucine as a new splicing inhibitor that blocks a late

48 MCT1-mediated uptake of a N-acetyl-L-leucine as a prodrug of leucine bypasses LAT1, the rat

49 the rationale for ongoing clinical trials of L-leucine as a therapeutic agent for DBA, and potentiall

50 upports the rationale for clinical trials of L-leucine as a therapeutic agent for DBA.

51 henylalanine, and N-(1-deoxy-D-fructos-1-yl)-L-leucine as the most effective inhibitors of colony for

52 rientation of the isopropyl methyl groups of l-leucine at the air-water interface.

53 otic mobilities of the enzyme and substrate, L-leucine beta-naphthylamide, allowed for efficient mixi

54 ter dipeptide surfactant poly(sodium undecyl-L-leucine-beta-alanine) (poly L-SULbetaA).

55 y signal transmitted to the active site upon l-leucine binding in the regulatory domain, a distance o

56 dy conformational changes to the enzyme upon l-leucine binding.

57 This is the first committed step in l-leucine biosynthesis.

58 s well as the poly(L-glutamatic acid)-b-poly(L-leucine) block copolypeptide, E60L20.

59 ssembly of a series of poly(L-lysine)-b-poly(L-leucine) block copolypeptides, KxLy, where x ranged fr

60 pholine)carbonyl-beta-(1-naphthyl)-L-alanine-L-leucine boronic acid (MLN-273), an analogue of the ant

61 up of activating amino acids is dominated by l-leucine but also includes l-methionine, l-isoleucine,

62 variants that have significant affinity for l-leucine but lack biphasic inhibition kinetics.

63 L since in the presence of BCH inhibition by L-leucine but not by L-lysine is sodium dependent.

64 L-Leucine, but not D-leucine, was converted to acetone w

65 ased maternal-fetal transfer of L-serine and L-leucine, but not glycine, following boluses of specifi

66 roate, which is reductively aminated back to L-leucine by leucine dehydrogenase in the presence of am

67 itaconate resistance mechanism in Mtb and an l-leucine catabolic pathway that proceeds via an unprece

68 this pathway, Rv2498c, also participates in l-leucine catabolism.

69 zed as follows: whole-cell biocatalyst 0.8 g/L, leucine concentration 13.1 g/L, temperature 35 degree

70 indicated that the specific concentration of L-leucine could decrease the umami of the tea.

71 table substrates of glutamate dehydrogenase, L-leucine dehydrogenase, L-phenylalanine dehydrogenase,

72 ounds is the incorporation of l-tyrosine- or l-leucine-derived 4-alkyl-l-proline derivatives (APDs) i

73 recombinant ALD1 transaminates l-methionine, l-leucine, diaminopimelate, and several other amino acid

74 ment of mice with N-(1-deoxy-D-fructos-1-yl)-L-leucine did not have significant antimetastatic effect

75 L-leucine plus L-isoleucine; (f) L-isoleucyl-L-leucine dipeptide; (g) L-leucyl-L-isoleucine dipeptide

76 (a) control; (b) WPH; (c) L-isoleucine; (d) L-leucine; (e) L-leucine plus L-isoleucine; (f) L-isoleu

77 of L-glutamine out of cells and transport of L-leucine/EAA into cells.

78 bitor, and N-(9-fluorenyl-methyloxycarbonyl)-L-leucine (F-L-Leu), a peroxisome proliferator-activated

79 Templates containing D- and L-leucines formed only a single H-bond.

80 seven of those polar metabolites (L-serine, L-leucine, glucose, fructose, myo-inositol, citric acid

81 ght individual amino acids--L-phenylalanine, L-leucine, glycine, L-lysine, L-arginine, L-cysteine, L-

82 no acid glycine, i.e., poly sodium N-undecyl L-leucine-glycine (poly L-SULG) and poly sodium N-undecy

83 t total synthesis of flutimide starting from L-leucine has been described.

84 d viscosities of L-glycine, beta-alanine and L-leucine have been determined in water and in aqueous s

85 the mTOR pathway, and this is accentuated by L-leucine in both Rps19 and Rps14 morphants.

86 LLKLLLLKLLLLK (KL4), in which K = lysine and L = leucine, in an aqueous dispersion of phospholipids (

87 h human chorionic gonadotropin secretion and L-leucine influx through system L were suppressed.

88 410F mutant form of MtIPMS is insensitive to l-leucine inhibition, suggesting that this residue has c

89 had wide-ranging effects on the kinetics of l-leucine inhibition, with some modest effects on the ki

90 3H-labeled FDG, thymidine, L-methionine and L-leucine into the cells was determined in the presence

91 N-acetyl-D,L-leucine is approved in France for vertigo and its L-en

92 A surprising discovery was that L-leucine is sensed by Tar as an attractant at low conce

93 ET tracers (FDG, thymidine, L-methionine and L-leucine) is affected by acute or chronic hyperglycemia

94 To address these critical gaps, N,N-dimethyl-l-leucine (l-DiLeu) tags are first validated as novel ch

95 l-L-valine (L-SUV), and sodium N-undecylenyl-L-leucine (L-SUL), were also used in this study, and the

96 his study were sodium N-undecylenyl-L-valine-L-leucine (L-SUVL), and sodium N-undecylenyl-L-leucine-L

97 gh over other amino acids, such as L-serine, L-leucine, L-aspartic acid, L-glutamic acid, histamine,

98 transport rates for L-serine, L-citrulline, L-leucine, L-cystine or 2-deoxyglucose.

99 ormamide (DMF), methyl salicylate, caffeine, l-leucine, l-histidine, loratadine, ibuprofen, acetamino

100 ontaining 0.03-24% L-threonine, D-threonine, L-leucine, L-lysine, L-glutamic acid, or diglycine with

101 Uptake of tritiated thymidine, L-leucine, L-methionine and FDG into two human tumor cel

102 o tumor cells of several tracers (thymidine, L-leucine, L-methionine and FDG) in the presence of eith

103 ctants, the polymers of sodium N-undecylenyl-L-leucine-L-leucine (L-SULL), sodium N-undecylenyl-L-val

104 ymes synthesize a common dipeptide fragment, l-leucine-l-O-isoindolinone-homoserine (l-Leu-l-Isd), wh

105 L-leucine (L-SUVL), and sodium N-undecylenyl-L-leucine-L-valine (L-SULV).

106 ogue, identified N-(1-deoxy-D-lactulos-1-yl)-L-leucine (Lac-L-Leu), N-(1-deoxy-D-fructos-1-yl)-D-leuc

107 L-tryptophan ("Trp") and L-leucine ("Leu"), when administered intraduodenally, in

108 ized using the lysosomotropic agent L-leucyl-L-leucine methyl ester (Leu-Leu-OMe).

109 Killing monocytes with l-leucine methyl ester abolished these T cell-monocyte c

110 abilization by lysosomotropic agent l-leucyl-l-leucine methyl ester that allows cytosolic release of

111 -l-valine, and a dipeptide, N-acetyl-l-valyl-l-leucine (N-Ac-VL), were studied via one- and two-dimen

112 on: benzoic acid, 2-(ethylthio)-ethyl ester, l-Leucine-N-isobutoxycarbonyl-N-methyl-heptyl and isorha

113 emonstrate that orally administered N-acetyl-L-leucine (NALL) significantly improved motor and cognit

114 valuated the safety and efficacy of N-acetyl-l-leucine (NALL), an agent that potentially ameliorates

115 pA1-575 can be covalently aminoacylated with l-leucine on the peptidyl carrier protein 1 domain.

116 and stimulation of the mTOR pathway through l-leucine or its metabolite alpha-KIC can partially resc

117 nine recognition enable spores to respond to L-leucine or L-serine.

118 detected for the larger CepA constructs with l-leucine or other expected amino acid substrates, sugge

119 rameters kcat and K(m) for the hydrolysis of L-leucine p-nitroanilide (L-pNA) revealed a change in an

120 with A (alanine), D (aspartate), K (lysine), L (leucine), P (proline), and W (tryptophan).

121 The hydrolysis of L-leucine-p-nitroanilide was measured spectrophotometric

122 l-leucine partly rescued protein synthesis and rRNA prod

123 b) WPH; (c) L-isoleucine; (d) L-leucine; (e) L-leucine plus L-isoleucine; (f) L-isoleucyl-L-leucine d

124 sin of N-(4-methoxyphenylazoformyl)-L-leucyl-L-leucine plus some congeneric peptides provides a highl

125 amino-acid transporters, but a single System L ('leucine-preferring system') transporter, Slc7a5, med

126 mine with the acid chloride of N(alpha)-Fmoc-L-leucine provided a N(alpha)-Fmoc-N-(benzoyloxy)-L-leuc

127 ic labeling with deuterated (isopropyl-d(7))-L-leucine revealed that the isopropyl carbons give rise

128 Administration of L-leucine significantly improved the anemia in Rps19-def

129 l-leucine stimulation of the mTOR pathway partially resc

130 Polysodium N-undecenoxycarbonyl-L-leucine sulfate (poly-L-SUCLS) and polysodium N-undece

131 The polysodium N-undecenoyl-l-leucine sulfate shows distinct tubular structure, whil

132 ctivation of the mTOR pathway in response to L-leucine supplementation was retained, suggesting a pos

133 ic amino acid residue L-4-methylproline from L-leucine, support the involvement of this cluster in no

134 ic amino acid residue L-4-methylproline from L-leucine, support the involvement of this gene cluster

135 yl acrylate and an imino ester prepared from l-leucine t-butyl ester hydrochloride and 2-thiazolecarb

136 et is synthesized in seven linear steps from l-leucine t-butyl ester hydrochloride with all three iso

137 ubject to slow-onset, feedback inhibition by l-leucine, the first instance of an allosteric regulator

138 ep eutectic solvent (AABNADES) consisting of L-leucine, thymol, and lactic acid developed as a media

139 Binding of L-leucine to an enzyme variant (Y410F) that is kinetical

140 y of fetal arterial boluses of L-alanine and L-leucine to stimulate release of amino acids from the p

141 mbin, and angiotensin II likewise stimulated L-leucine transport by inducing LAT1 expression.

142 Treatment of SMCs with PDGF stimulated L-leucine transport in a concentration- and time-depende

143 act with the large neutral amino acid system L (leucine) transporter.

144 Concomitantly, l-leucine treatment partially improved cohesinopathy emb

145 atients with NPC was measured after N-acetyl-l-leucine treatment, which has been recently shown to ha

146 we have validated the therapeutic effect of L-leucine using our recently generated mouse model for R

147 In the EDL, incubation with 100 or 200 mumol/l leucine versus no added leucine suppressed the activit

148 When 13.1 g/L leucine was added at 2-h intervals (from 0 to 22 h, 12

149 ectivity (alpha) and resolution (R(s)) for D,L-leucine were 1.16 and 1.64, respectively.

150 o identified a marker of nutritional status, l-leucine, which lowers the progesterone threshold, indi

151 and the statine moiety can be replaced with L-leucine while retaining anti-HIV activity.

152 Transamination of L-leucine with alpha-ketoglutarate results in formation

153 rom acetate, L-phenylalanine, L-cysteine and L-leucine with trichloroleucine as a direct precursor by

154 the two nuclear receptor-interacting LXXLL (L, leucine; X, any amino acid) motifs in PBP in a ligand